Bristol-Myers Squibb Reports First Randomized Study Evaluating Opdivo+Yervoy Regimen Shows Superior Efficacy Related to Yervoy Alone
April 20, 2015 at 08:31 AM EDT
Bristol-Myers Squibb Company (NYSE: BMY) today announced positive results from a Phase II trial (CheckMate -069), evaluating the Opdivo ...
